Introduction {#sec1_1}
============

Small-cell lung cancer (SCLC), which comprises approximately 10--15% of all lung cancers \[[@B1]\], is a neuroendocrine tumor, previously known as oat cell carcinoma, that is closely linked with tobacco smoking \[[@B2]\] and characterized by an aggressive and rapid pattern of metastases, limited treatment options following progression, and overall poor prognosis \[[@B3]\]. The disease is traditionally divided into two stages: limited-stage disease (LD), confined to one hemithorax encompassable in a single radiation port, and extensive-stage disease (ED), extending beyond those boundaries \[[@B4]\], which comprise the vast majority of patients at initial diagnosis \[[@B5], [@B6]\]. For extensive-disease SCLC, the standard first-line regimen is etoposide-platinum (EP) doublets followed by topotecan, approved for second-line treatment, since progression is the rule after first-line EP despite the fact that SCLC is initially chemosensitive (with response rates to first-line treatment on the order of 70--90% in LS disease and 50--60% in ED disease \[[@B7]\]). In ED, despite a response rate of 15--28% \[[@B8]\] to topotecan \[[@B9]\], the median OS rarely exceeds 6 months. According to the current nomenclature \[[@B10]\], SCLC is categorized as 'sensitive relapsed' (PFS \<3 months), 'resistant' (PFS \<3 months) and 'refractory' (progression through first-line treatment). In general, subsequent readministration of EP doublets is contraindicated in resistant and refractory disease due to the likelihood of undue toxicities (myelosuppression and nephrotoxicity, for example) without benefit, since therapeutic resistance in these contexts is, with exceptions, construed as a stable and immutable trait \[[@B11]\]. No guidelines are available about platinum doublet rechallenge after initial and secondary failures.

Pretreatment or priming with epigenetic inhibitors, like the approved DNA demethylators, e.g., 5-azacitidine (azacitidine, AZA) and 2′-deoxy-5-azacitidine (decitabine, DAC) and the histone deacetylases, e.g., vorinostat and romidepsin as well as experimental RRx-001, has been identified as a nascent strategy, still in its infancy, to attenuate or reverse resistance to chemotherapy and immunotherapy \[[@B12], [@B13], [@B14]\], particularly in non-small cell and ovarian cancers. The term 'episensitization \[[@B15]\]' has been coined for this priming paradigm. RRx-001, in particular, has demonstrated evidence of episensitization to refractory irinotecan in the context of a Phase II clinical trial entitled ROCKET in metastatic colorectal cancer \[[@B16], [@B17], [@B18]\].

TRIPLE THREAT (NCT02489903) is an ongoing open-label Phase II trial in non-small lung cancer, SCLC and high-grade neuroendocrine tumors, which investigates a resensitization strategy to previously administered, but now refractory, platinum doublets following treatment with and progression on (by RECIST vs. 1.1 criteria) single agent RRx-001 mixed ex vivo with 100 ml of autologous blood prior to infusion. The rationale for this unusual method of administration is related to the red blood cell partitioning of RRx-001, which binds with high affinity to a cysteine residue in the β-chain of Hb (Cys β93), displacing nitric oxide (NO) in the process. When NO is displaced in vivo via standard intravenous infusion, it stimulates venous nociceptors, with a mild to moderate sensation of pain or discomfort for patients; however, in the infusion bag, mixed with blood, the NO is reabsorbed by the red blood cells, which appears to completely abrogate the hyperalgesia, resulting in a well-tolerated and rapid (\~30 min) infusion.

Herein, we report a case of a patient with extensive refractory ED-SCLC who was 'episensitized' to cisplatin and etoposide, with a partial response, after treatment with weekly intravenous RRx-001 autologous blood mix.

Case Report {#sec1_2}
===========

Patient 001--001, a 49-year-old male veteran, former smoker, with a diagnosis of extensive-stage SCLC, completed six cycles of carboplatin and etoposide in December 2012. Having progressed approximately 6 months later with 'sensitive relapsed' (PFS \>3 months) disease, he was enrolled on a clinical trial at the NIH in July 2013 where he received six cycles of cisplatin and etoposide followed by maintenance with the HDAC inhibitor belinostat. Approximately 1 year after completion of the NIH trial, with symptoms of fatigue and inappetence due to disease progression as well as dyspnea and decreased exercise tolerance from a large unilateral pleural effusion, he enrolled as the first patient (001--001) on the TRIPLE THREAT clinical trial at Walter Reed in June 2015. After the first dose of RRx-001, and continuing for the next 8--9 weeks, the patient reported a significantly increased appetite for and consumption of fried foods, specifically pork chops, and desserts, which led to dyspeptic symptoms. His fatigue, shortness of breath and exercise tolerance also significantly improved to the point that he resumed uphill running and lifting weights. A CT scan at 6 weeks (fig. [1](#F1){ref-type="fig"}), correlating with the symptomatic improvement, demonstrated near complete resolution of the unilateral malignant pleural effusion. In addition, his target lesions shrank by 7% (not shown).

Unfortunately, nearly 10 weeks after the start of TRIPLE THREAT, patient 001--001 developed 'travelers thrombosis' and pulmonary embolism presumably from a prolonged (10 h) car ride, which prompted the PI to discontinue RRx-001 on suspicion of symptomatic progression since the patient began to complain of fatigue and inappetence as well as dyspnea associated to pulmonary embolism, even though repeat CT scans did not confirm radiologic progression. At this point, per protocol, since the patient still met all inclusion/exclusion criteria, he was rechallenged for a third time with EP doublets and, despite expected toxicities of fatigue and anorexia, he reported improved performance status. At 6 weeks after reintroduction of therapy, repeat CT scans demonstrated a partial response with an approximate 32% decrease in tumor size (fig. [2](#F2){ref-type="fig"}). One month later, a confirmatory scan showed a 50% decrease in tumor size, indicative of continued cytotoxic activity.

Discussion {#sec1_3}
==========

To the best of our knowledge, TRIPLE THREAT is the first and only clinical trial to investigate resensitization or episensitization, since RRx-001 is an epigenetic inhibitor \[[@B19]\] in SCLC as well as NSCLC and neuroendocrine tumors. As a highly aggressive tumor with a uniformly dismal prognosis and an unmet need for effective therapeutic options, SCLC is extremely difficult to treat: the median survival time following recurrence rarely exceeds 6 months, the 2-year survival is \<10%, and there are virtually no 5-year survivors \[[@B20]\], requiring innovative strategies to address the difficult challenge of salvage treatment of relapsed SCLC.

DNA methyltransferase and HDAC inhibitors have demonstrated the potential to reverse therapeutic resistance \[[@B21]\] in multiple tumor types because epigenetic alterations, an important driver of carcinogenesis and progression, are, in theory, reversible. Paradoxically, these alterations are also stably maintained through mitotic cell division, leading to a kind of epigenetic memory \[[@B22]\], with priming of responses to temporally separate and subsequent, rather than simultaneous, therapy since the induced pattern of gene transcription persists.

The clinical course of this SCLC patient (001--001) suggests, with the usual caveats about making generalizations from 'n-of-1' results, that reintroduction of etoposide-platinum after initial treatment with RRx-001, leading to episensitization, is a safe and effective strategy for solid tumor types previously treated with platinum doublet-based chemotherapy. The Phase II TRIPLE THREAT clinical trial is ongoing, having enrolled 5 patients to date, none of whom, besides patient 001--001, have progressed on RRx-001, and their data will also be reported, if episensitization, anticipated here as elsewhere, is demonstrated.
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